Biopharma research and development has traditionally followed a familiar model. Scientists identified a target, generated ...
The Association of the British Industry (ABPI) has welcomed a Budget measure that removes a value added tax (VAT) charge on ...
US AI native pharmaceutical company Formation Bio today announced the Formation Bio Drug Development Accelerator Fund, with ...
The Moscow Arbitration Court has rejected claims of the Russian pharmaceutical manufacturer Grotex to provide a compulsory ...
German biotech BioNTech and its Chinese partner DualityBio have reported that the Phase III DYNASTY-Breast02 trial of ...
US biotech Biogen (Nasdaq: BIIB) raised the lower end of its annual earnings guidance after third-quarter revenue rose 11% to ...
Pfizer’s Elrexfio meets primary endpoint in second Phase III myeloma trial, with higher infections
US pharma giant Pfizer said its Phase III MagnetisMM-32 trial of Elrexfio (elranatamab), a subcutaneous BCMA-CD3 bispecific antibody, met its primary endpoint at a prespecified interim analysis in ...
Japan’ Nxera Pharma today announces that it has exercised its option to license lucerastat from Idorsia and has entered into ...
A US federal judge has refused to block Eli Lilly’s advertising campaign comparing its obesity drug Zepbound (tirzepatide) ...
Swiss generic and biosimilars drugmaker Sandoz today presented its net-sales performance for the third quarter and first nine ...
Norwegian clinical-stage radiopharma company Oncoinvent, which is developing Radspherin, a receptor-independent ...
Swiss specialty drugmaker Ferring Pharmaceuticals has signed an agreement to acquire US biotechnology company Gameto for up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results